CBP-1018, a bi-ligand-drug conjugate treated in patients with advanced solid tumors: A phase I, multi-center, open-label, dose-escalation and dose expansion study

CBP-1018 - Coherent Biopharma

K. Li1; J. Wu1; S. Ye1; Y. liu1; H. Huang1; F. fan1; Y. lai1; S. Zhuang1; L. Zhou2; R. Huang3; Y. Teng3; X. Chai3; J. Zhang3; Y. Shi2; H. Huang1

Jul 27, 2023